Natural History and Predictors of Progression to Sjögren's Syndrome Among Participants of the Sjögren's International Collaborative Clinical Alliance Registry. Issue 2 (3rd January 2018)

• Record Type: Journal Article
• Authors: Shiboski, Caroline H.; Baer, Alan N.; Shiboski, Stephen C.; Lam, Mi; Challacombe, Stephen; Lanfranchi, Hector E.; Schiødt, Morten; Shirlaw, Penelope; Srinivasan, Muthiah; Umehara, Hisanori; Vivino, Frederick B.; Akpek, Esen; Bunya, Vatinee; Vollenweider, Cristina F.; Greenspan, John S.; Daniels, Troy E.; Criswell, Lindsey A.
• Other Names: Cox D. investigator.; Jordan R. investigator.; Lee D. investigator.; Sack K. investigator.; Whitcher J. investigator.; Lietman T. investigator.; McNamara N. investigator.; Wu A. investigator.; DeSouza Y. investigator.; Drury D. investigator.; Do A. investigator.; Scott L. investigator.; Nespeco J. investigator.; Whiteford J. investigator.; Margaret M. investigator.; Adler I. investigator.; Smith A. C. investigator.; Bisio A. M. investigator.; Gandolfo M. S. investigator.; Heidenreich A. M. investigator.; Chirife A. M. investigator.; Keszler A. investigator.; Daverio S. investigator.; Kambo V. investigator.; Jiang Y. investigator.; Xu D. investigator.; Su J. investigator.; Zhao Y. investigator.; Dong Y. investigator.; Du D. investigator.; Wang H. investigator.; Li Z. investigator.; Xiao J. investigator.; Wu Q. investigator.; Zhang C. investigator.; Meng W. investigator.; Zhang J. investigator.; Johansen S. investigator.; Hamann S. investigator.; Lindegaard J. investigator.; Schiødt Julie investigator.; Holm Helena investigator.; Helin P. investigator.; Ibsen P. investigator.; Manniche A. M. investigator.; Kreutzmann S. P. investigator.; Masaki Y. investigator.; Sakai T. investigator.; Sugai S. investigator.; Kitagawa K. investigator.; Shibata N. investigator.; Honjo M. investigator.; Kurose N. investigator.; Nojima T. investigator.; Kawanami T. investigator.; Sawaki T. investigator.; Fujimoto K. investigator.; Kirkham B. investigator.; Larkin G. investigator.; Odell E. investigator.; Morgan P. investigator.; Fernandes‐Naglik L. investigator.; Varghese‐Jacob B. investigator.; Seghal S. investigator.; Mishra R. investigator.; Massaro‐Giordano M. investigator.; Abboud S. K. investigator.; Pinto A. investigator.; Sia Y. W. investigator.; Dow K. investigator.; Ingrodi S. investigator.; Henderson W. investigator.; Gourin C. investigator.; Keyes A. investigator.; Mascarenhas J. investigator.; Das M. investigator.; Kumar A. investigator.; Joshi Pallavi investigator.; Banushree R. investigator.; Kim U. investigator.; Babu B. investigator.; Ram A. investigator.; Kannappan Saravanan investigator.; Kalyani N. investigator.;
• Is Part Of: Arthritis care & research. Volume 70:Issue 2(2018)
• Page Start: 284
• Page End: 294
• Publication Date: 2018-01-03
• Subjects: Arthritis -- Periodicals; Rheumatism -- Periodicals; 616.72
• DOI: 10.1002/acr.23264
• Languages: English
• ISSNs: 2151-464X

Abstract

Abstract : Objective: To explore changes in the phenotypic features of Sjögren's syndrome (SS), and in SS status among participants in the Sjögren's International Collaborative Clinical Alliance (SICCA) registry over a 2–3‐year interval. Methods: All participants in the SICCA registry who were found to have any objective measures of salivary hypofunction, dry eye, focal lymphocytic sialadenitis in minor salivary gland biopsy, or anti‐SSA/SSB antibodies were recalled over a window of 2 to 3 years after their baseline examinations to repeat all clinical examinations and specimen collections to determine whether there was any change in phenotypic features and in SS status. Results: As of September 15, 2013, a total of 3, 514 participants had enrolled in SICCA, and among 3, 310 eligible, 771 presented for a followup visit. Among participants found to have SS using the 2012 American College of Rheumatology (ACR) classification criteria, 93% again met the criteria after 2 to 3 years, and this proportion was 89% when using the 2016 ACR/European League Against Rheumatism (EULAR) criteria. Among those who did not meet ACR or ACR/EULAR criteria at baseline, 9% and 8%, respectively, had progressed and met them at followup. Those with hypergammaglobulinemia and hypocomplementemia at study entry were, respectively, 4 and 6 times more likely to progress to SS by ACR criteria than those without these characteristics (95% confidence interval 1.5–10.1 and 1.8–20.4, respectively). Conclusion: While there was stability over a 2–3‐year period of both individual phenotypic features of SS and of SS status, hypergammaglobulinemia and hypocomplementemia at study entry were predictive of progression to SS.